AnaptysBio
ANAB
114 hedge funds and large institutions have $831M invested in AnaptysBio in 2022 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 38 increasing their positions, 36 reducing their positions, and 21 closing their positions.
36,524% more call options, than puts
Call options by funds: $6.23M | Put options by funds: $17K
31% more capital invested
Capital invested by funds: $633M → $831M (+$198M)
4.74% more ownership
Funds ownership: 110.55% → 115.29% (+4.7%)
6% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 36
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
8% less funds holding
Funds holding: 124 → 114 (-10)
48% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$39.2M |
| 2 |
DM
Deerfield Management
New York
|
+$16.3M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$7.01M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$4.44M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$3.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$13.6M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$9.2M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$7.33M |
| 4 |
EP
Eversept Partners
New York
|
-$3.71M |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
-$1.67M |
ANAB Hedge Fund Activity: Q3 2022 in Review
114 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in AnaptysBio (ANAB) for Q3 2022, worth a combined $831M — up 31% from $633M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of ANAB and 11 opened new positions — a net loss of 10 holders — while 36 trimmed existing stakes and 38 added.
The largest buyer was Point72 Asset Management, adding an estimated $39.2M. The largest seller was Soleus Capital Management, cutting an estimated $13.6M.
- 114 institutional investors held AnaptysBio (ANAB) as of Q3 2022, down from 124 in Q2 2022.
- Funds reported $831M of AnaptysBio stock for Q3 2022, up 31% quarter-over-quarter.
- 11 funds opened new AnaptysBio positions in Q3 2022 and 21 closed out, a net change of -10 holders.
- The largest AnaptysBio buyer in Q3 2022 was Point72 Asset Management, an estimated $39.2M added.
- The largest AnaptysBio seller in Q3 2022 was Soleus Capital Management, an estimated $13.6M sold.
Based on aggregated 13F filings for Q3 2022.